Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo
Important Safety Information | Patient Site
Prescribing Information
    • Why Esperoct®
    • Pharmacology
    • Mechanism of Action
    • Prophylaxis
    • On Demand & Perioperative
    • Safety Profile
    • Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Prescribing Information
Important Safety Information | Patient Site

Talk to us about Esperoct®.

Flexibility and bleed protection on the go for patients with hemophilia A1,a

Why Esperoct®?

Flexibility and bleed protection on the go for patients with hemophilia A1,a

Why Esperoct®?

Actor portrayal

Actor portrayal

aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.

Temperature
stabilityb

Thermometer icon

For greater flexibility1-6,b>

Individualized PPx dosing frequencyc

Esperoct® vial

For bleed protection1,7,8>

Long-term bleed protectiond,e

Shield with blood droplet icon

For all ages1,7,8>

Approved for
all ages

People of all ages icon

From pediatric to adult1>

bPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.

cBased on bleeding episodes. See Prescribing Information for complete dosing instruction.

dMedian annualized bleeding rate (ABR) from the main phase (1.2) and the main and extension phases (0.8) of the pivotal clinical trials in previously treated patients (PTPs) aged ≥12 years old (n=177) with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days for up to 6.6 years.

eMedian ABR of 0.8 from the main and extension phases of previously treated children aged <12 years old (n=68) who took Esperoct® 60 IU/kg (range 50-75 IU/kg) twice weekly for up to 5.4 years.

PPx= prophylaxis

Thrombotic events icon

A proven safety profile with long-term data1

Research shows 0 thrombotic events across 5 clinical trials.1 Learn more about our long-term data and the latest recommendations for treating your patients.

View safety data
See study design

High trough levels for a broad range of patients1

Esperoct® has a longer half-life compared to SHL FVIII products. Trough levels stabilized in the range of mild/moderate hemophilia,~5%, for a majority of the time in adults and adolescents.9,10,c

Find out how

Tammy has
hemophilia A
and uses Esperoct®

cPost hoc analyses were performed on data from the pathfinder2 trial of patients aged ≥12 with severe hemophilia A who received prophylaxis, every 4 days. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates (n=61) and mean factor VIII trough levels (n=53, patients who received up to ≥6 years of treatment with Q4D prophylaxis). Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.10


Adult and child posing

Individualize prophylactic dosing frequency for your patients’ needs1,d

Esperoct® is an extended half-life (EHL) rFVIII product.1

One proven starting dose for adults & adolescents

Adults & Adolescents

One proven starting dose for children

Children

dBased on bleeding episodes

Esperoct® is ready when your patients are

Bradley standing with his arms crossed

Bradley has hemophilia A and uses Esperoct®.

Discover how

Start your patients on Esperoct®

Esperoct® package

Novo Nordisk offers support programs to help qualifying patients get started.

See how we can help

Create your account

Gain access to more resources and services for you and your patients—it only takes a minute.

Get started

With a novoMEDLINK™ account, you can:

Injection and pill icon

Request product samples

Book icon

Order educational materials

List icon

Access the latest product information

Note icon

Receive personalized updates

Study design

Giangrande et al (2017 and 2020)
pathfinder2 phase 3 clinical trial: main phase and extension

Patients: Previously treated males aged 12–66 years with severe congenital hemophilia A (FVIII activity <1%) and at least 150 exposure days to any FVIII products.11

Study design: Multinational, open-label, non-randomized trial evaluating safety, pharmacokinetics, and clinical efficacy of Esperoct® when used for prophylaxis and treatment of bleeds. During the main phase, 175 patients received routine prophylaxis (50 IU/kg every 4 days), and 12 adults elected to be treated on-demand. A subset of patients (n=150) continued on in extension phase part 1; 139 continued into the non-randomized extension part 2, with 113 completing the trial.7,11

Co-primary endpoints: Incidence of FVIII inhibitors ≥0.6 BU (Bethesda units) and ABR (annualized bleeding rate) for patients on a prophylaxis regimen.11

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

References:

  1. Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.                             
  2. Adynovate® [package insert]. Lexington, MA: Baxalta US Inc; 2023.                                 
  3. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2023.                           
  4. Altuviiio® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.                   
  5. Eloctate® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.                   
  6. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
  7. Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(suppl 1):5-14.
  8. Šaulytė Trakymiene S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5. J Thromb Haemost. 2020;18(suppl 1):15-25.
  9. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013;11(4):670-678.
  10. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2021;28(1):27-35.
  11. Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252-261.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US24ESP00008 August 2024

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials